Geode Capital Management LLC Has $1.85 Million Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Geode Capital Management LLC raised its stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 14.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,138,309 shares of the biopharmaceutical company’s stock after buying an additional 272,123 shares during the quarter. Geode Capital Management LLC owned about 1.02% of Sangamo Therapeutics worth $1,853,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. XTX Topco Ltd lifted its position in Sangamo Therapeutics by 167.8% in the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 64,981 shares in the last quarter. State Street Corp raised its stake in shares of Sangamo Therapeutics by 28.0% in the 3rd quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company’s stock valued at $576,000 after purchasing an additional 145,400 shares during the period. FMR LLC lifted its holdings in shares of Sangamo Therapeutics by 16.5% in the third quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company’s stock valued at $471,000 after purchasing an additional 77,032 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Sangamo Therapeutics by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock worth $956,000 after buying an additional 57,125 shares during the period. Finally, Meritage Portfolio Management grew its holdings in shares of Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 6,740 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

Wall Street Analyst Weigh In

SGMO has been the topic of several research reports. Jefferies Financial Group cut their target price on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, December 31st. Wells Fargo & Company cut their price objective on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 31st. Truist Financial raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Friday, December 13th. Barclays boosted their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Thursday, January 2nd. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.50.

Sangamo Therapeutics Trading Down 11.3 %

SGMO stock opened at $1.22 on Thursday. Sangamo Therapeutics, Inc. has a 1-year low of $0.30 and a 1-year high of $3.18. The business’s 50 day simple moving average is $2.09 and its 200 day simple moving average is $1.25. The firm has a market capitalization of $253.51 million, a PE ratio of -1.62 and a beta of 1.29.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.07. The firm had revenue of $49.41 million for the quarter, compared to the consensus estimate of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same period in the previous year, the company earned ($0.34) earnings per share. As a group, sell-side analysts predict that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.